



Cross – Validation; ensuring quality and consistency

Biological samples have been tested by **different partners across Europe** to ensure validation of the results. This information is **invaluable and essential when translating research into clinical practice.**

Ethics, Education and Training

Partners have debated the ethics of the Riset research programme **together.** A **collaboration** between partners systematically **reviewed the information provided to each patient participating in a Riset study and the consent forms** to ensure the patients received the most appropriate information explained in a clear and accurate way.

The Riset Partners have attended public and professional meetings and **shared their knowledge** at training events set up by the consortium to ensure a new, younger generation of **scientists and clinicians are able to access the most up to date theories and benefit from the experience and knowledge of their senior colleagues.**

The consortium has worked together to publish data, posters and other articles about the project to ensure its **findings are widely disseminated and that patients continue to benefit from the enormous amount of work that has been undertaken.** A wealth of crucial data has been **shared and analysed** on the consortium database in order **to maximise the research results.**

Co-operating to improve the health of EU citizens

The Riset project

Collaborative Research – the benefits of working together

The Riset Consortium has **created a competitive and innovative European task force** to translate advances in transplantation into clinical practice. To this end Riset partners – clinicians, scientists and industry– **have worked together in many ways** to design, implement clinical studies and to follow up patients enrolled in Riset studies, both clinically and immunologically. **These collaborations may eventually lead to state of the art, more personalised treatment for transplant patients.** Working together in the laboratory and the clinic Riset collaborations have:

- **Tracked the immune system of transplant recipients** to chart their immune status and reconstitution after treatment. This has contributed to **the search for valuable biomarkers** which will be used to identify patients at increased or reduced risk of rejection or of losing their transplant
- **Investigated the dynamics of gene expression** in transplant patients and analysed how patients have responded to certain treatment protocols using cell therapy. This will help to **optimise the treatment transplant patients receive in the future**
- **Identified and prioritized genes** to be analysed in different experimental systems - **pooling knowledge to improve research results and identify new targets for future drug discovery**

Maximising knowledge and continuing research

Partners have **pooled knowledge to write critical analyses** of state of the art in transplantation research for professionals working in the field and for patients. Riset has enabled partners to **develop highly productive working relationships** facilitating **training and mobility of scientists as well as the formation of new consortia** that will be competitive for future research funding. This will allow the **research undertaken within Riset to grow and develop,** ensuring the knowledge gained leads to **further discoveries that will benefit transplant recipients.**

Developing New Tests and Tools

Co-operation has led to the development of new investigative tools, advances in technology and to **new products to aid research and clinical practice.** Partners have tried out **new techniques and provided feedback** on their findings to help **refine the protocols, which will ultimately benefit patients.**

Sharing new reagents to use in different models led to the **development and validation of new assays (tests).** Patients will benefit from this **stringent approach to research and from more effective tests to monitor their progress after transplantation.**